Vir Biotechnology (NASDAQ:VIR) Stock: Insider Verneuil Vanina De Sells 1,343 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 1,343 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $11.33, for a total transaction of $15,216.19. Following the completion of the sale, the executive vice president directly owned 112,600 shares of the company’s stock, valued at $1,275,758. The trade was a 1.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 3rd, Vanina de Verneuil sold 2,407 shares of Vir Biotechnology stock. The stock was sold at an average price of $11.10, for a total transaction of $26,717.70.

Vir Biotechnology Stock Down 6.4%

Shares of VIR stock opened at $11.02 on Friday. The stock has a market capitalization of $1.86 billion, a PE ratio of -8.75 and a beta of 1.70. Vir Biotechnology, Inc. has a 52-week low of $4.82 and a 52-week high of $12.19. The stock’s 50-day moving average price is $11.01 and its 200 day moving average price is $9.58.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.98 million. The company’s revenue for the quarter was down 178.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.17) earnings per share. Analysts expect that Vir Biotechnology, Inc. will post -1.84 earnings per share for the current fiscal year.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Needham raised its price target to $20 from $18 and maintained a Buy rating, signaling a more bullish analyst view. Needham rating details
• Positive Sentiment: Vir said it expects to present topline Phase 3 ECLIPSE 1 results for elebsiran and tobevibart at AASLD’s 2026 liver meeting. The data could be an important catalyst for the company’s hepatitis delta program. AASLD presentation announcement
• Neutral Sentiment: Management expects its cash runway to extend into the second half of 2028, helping fund development, while the timing and outcome of upcoming clinical catalysts remain uncertain. Cash runway and trial timing
• Neutral Sentiment: An executive’s small stock sale was made under a pre-arranged plan to cover tax withholding on vested equity awards, making it a limited signal about the company’s outlook. Insider transaction details
• Negative Sentiment: Third-quarter revenue was negative $0.19 million, below the roughly $0.98 million expected and down 178.3% year over year. Although the loss of $0.57 per share was narrower than analysts’ estimates, the revenue miss may be overshadowing that earnings beat. Q3 results and corporate update

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp boosted its holdings in Vir Biotechnology by 10.1% in the third quarter. Fifth Third Bancorp now owns 29,064 shares of the company’s stock worth $325,000 after purchasing an additional 2,669 shares during the period. Maryland State Retirement & Pension System lifted its position in shares of Vir Biotechnology by 58.5% in the 3rd quarter. Maryland State Retirement & Pension System now owns 28,033 shares of the company’s stock worth $313,000 after buying an additional 10,346 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Vir Biotechnology by 4.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,135 shares of the company’s stock valued at $616,000 after buying an additional 2,164 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in shares of Vir Biotechnology by 3.3% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 28,468 shares of the company’s stock valued at $318,000 after buying an additional 900 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Vir Biotechnology in the 3rd quarter valued at about $97,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on VIR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a research note on Monday, September 28th. Needham & Company LLC boosted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday. Zacks Research cut shares of Vir Biotechnology from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. Finally, Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.14.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.